This study is testing a new drug called MEN2312 for people with advanced breast cancer. MEN2312 is a lysine acetyltransferase 6 (KAT6) inhibitor. Advanced breast cancer means the cancer has spread and can't be cured. To join, you must have certain genetic changes in your breast cancer and have tried other treatments like hormone therapy and a specific type of medicine called a cyclin-dependent kinase 4 and 6 inhibitor.

Key Points:

• The study is for people with advanced breast cancer who have tried other treatments.
• You cannot join if the cancer has spread to your brain or if you have very serious organ involvement.
• Participation includes monitoring for any side effects or health changes.

Before joining, talk to your doctor to see if this study is a good fit for you. Keep in mind that there are more rules about who can join the study, so it's important to discuss all details.